Pharmacyclics Signs US$975 M Agreement with Janssen Biotech for Mid-Stage Btk Inhibitor

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)

Published: 6 Jan-2012

DOI: 10.3833/pdr.v2012.i1.1645     ISSN: 1756-7874

Section: Licensing



Pharmacyclics has entered into a global partnership with Johnson & Johnson’s Janssen Biotech unit for its mid-stage haematological cancer programme, PCI-32765...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details